The Detection and Clinical Utilization of Chimerism and HLA Loss Relapse

Date/Time: Wednesday, September 29, 2021 - 2:15 PM to 3:45 PM
Log in to Add to My Schedule


Chimerism testing is performed for patients who have received a hematopoietic stem cell transplant or solid organ such as a Liver transplant. The test involves identifying the genetic profiles of the recipient and the donor and then evaluating the extent of the mixture in the recipient’s post-transplant blood, bone marrow, and cell subsets. The main goal of the test is to predict adverse events, such as disease relapse, graft rejection, and graft-versus-host disease, to intervene with appropriate therapy.

HLA-loss relapses are defined as those in which the recipient tumor DNA showed genomic loss of the donor-recipient mismatched HLA. Detection of HLA-loss at the onset of relapse could help in clinical practice to select appropriate rescue treatment.

In this session, we have invited a renowned clinician to discuss how Chimerism and HLA Loss relapse testing is used clinically today. We also asked lab experts to make a comparison of the main test methods and share analysis results of the current state of affairs, challenges, gaps, and future directions.


Clinical utilization:  The value of detecting Chimerism and HLA loss, the importance of test sensitivity/frequency/subsets, in determining engraftment/relapse/MRD/HLA Loss


Current field practice/performance: The current state of affairs of ASHI/CAP PT, challenges and gaps, and the future directions

Methods comparison: The difference between detecting Chimerism and HLA Loss, the pros/cons among STR, qPCR, NGS, HLA Markers vs Non-HLA markers